Aflibercept 8 mg first to safe sustained vision gains with bigger than 70% of sufferers extended to intervals between 16 and 24 weeks in moist age-linked macular degeneration at two years

Summary

Outcomes from PULSAR existing lengthy duration of time efficacy of aflibercept 8 mg with extended dosing intervals reaching as a lot as 24 weeks and vision enhancements a corresponding to Eylea™ (aflibercept 2 mg) at fastened 8-weekly dosing over two years / Sufferers randomized at baseline to aflibercept 8 mg 16-week dosing routine obtained a median of 8.2 injections (4.6 fewer than Eylea (aflibercept 2 mg)) over two years / Security profile of aflibercept 8 mg in neovascular (moist) age-linked macular degeneration (nAMD) remains a corresponding to Eylea (aflibercept 2 mg) without a new signals identified